Libella Gene Therapeutics is evaluating the safety and tolerability of AAV-TERT currently with the goal of treating critical limb ischemia, Alzheimer’s disease, and aging. The gene discussed is TERT; the disease is early-onset autosomal dominant Alzheimer disease.